BioLife Solutions (NASDAQ:BLFS) EVP Aby Mathew Sells 631 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 631 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $25.13, for a total transaction of $15,857.03. Following the sale, the executive vice president directly owned 349,755 shares in the company, valued at $8,789,343.15. This trade represents a 0.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

BioLife Solutions Price Performance

BLFS stock traded up $0.68 during midday trading on Thursday, hitting $25.69. 53,084 shares of the stock traded hands, compared to its average volume of 443,760. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62. The stock’s fifty day simple moving average is $26.34 and its 200-day simple moving average is $24.52. The firm has a market cap of $1.24 billion, a P/E ratio of -368.03 and a beta of 1.93.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLFS. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in BioLife Solutions during the second quarter worth about $205,000. Forum Private Client Group LLC acquired a new position in BioLife Solutions in the second quarter valued at approximately $232,000. Comerica Bank lifted its holdings in BioLife Solutions by 5.2% in the first quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 746 shares during the last quarter. Royal Bank of Canada grew its position in BioLife Solutions by 762.8% in the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after acquiring an additional 617,320 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of BioLife Solutions during the 2nd quarter worth $286,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a research report on Monday, November 24th. Finally, Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $30.75.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.